Lorna Jane, an Australian activewear company, was recently fined AU$5 million after claiming that its new line of active clothing can stop the spread of COVID-19. The firm said that its clothing could eliminate the virus, thus preventing its spread.
According to BBC News, Lorna Jane released advertisements that say it is using a groundbreaking technology called LJ Shield for its clothing line. It was claimed that this could stop the "transfer of all pathogens."
What the court says on Lorna Jane’s claims
Based on the report, a judge said in a ruling that the company’s claim about LJ Shield is "exploitative, predatory and potentially dangerous." The legal action against Lorna Jane was filed by the Australian Competition & Consumer Commission (ACCC) after the firm started selling its clothing in July amid the COVID-19 pandemic.
The verdict was said to have been released by the federal court on Friday, July 23. The judge said that based on investigations, Lorna Jane has been telling the consumers it has a “reasonable scientific or technological basis" for its claims about its clothing with the LJ Shield.
However, the judge said there was actually no scientific basis for such a claim. For this false and misleading representation to the public, the court slapped the company with a hefty fine.
"This was dreadful conduct as it involved making serious claims regarding public health when there was no basis for them," chairman of the ACCC, Rod Sims, said. "The whole marketing campaign was based upon consumers' desire for greater protection against the global pandemic."
Lorna Jane accepts the judge’s decision
The company was said to have accepted the verdict but explained, it was also misled by its supplier. Lorna Jane claimed its supplier sold them a product that did not deliver what it claimed to be, and they are referring to what they called the LJ Shield technology that is supposed to be anti-viral and anti-bacterial.
Meanwhile, it was learned that this is not the first time that Lorna Jane was fined. As per The Guardian, just in July 2020, the company was fined $40,000 for its failure to seek proper approval for ads from the Therapeutic Goods Administration. As for this new issue, the company issued an apology for its customers while continuing to blame its supplier for the issue.


Federal Reserve Balance Sheet Reduction: Brookings Research Outlines Possible Path Forward
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation
Iran-Israel Missile Strikes Continue Amid Mixed Signals on U.S.-Iran Diplomacy
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion
Gold Prices Surge on U.S.-Iran Ceasefire Reports
Wall Street Slides as Iran War Uncertainty, Oil Surge, and AI Fears Rattle Markets
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round
Bank of Japan Eyes April Rate Hike Despite Inflation Dip, ING Says
Australia's Inflation Eases in February but Core Pressures Persist
Australia-EU Free Trade Deal Signed After Years of Negotiations
U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion
Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 



